Velagliflozin, sold under the brand name Senvelgo, is an antidiabetic medication used for the treatment of cats.[2][4] Velagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.[5] It is taken by mouth.[2]

Medical uses

Velagliflozin is indicated to improve glycemic control in otherwise healthy cats with diabetes not previously treated with insulin.[2][4][5]

References

  1. ^ "Notice: Multiple additions to the Prescription Drug List (PDL) [2024-10-18]". Health Canada. 18 October 2024. Retrieved 25 October 2024.
  2. ^ a b c d "Senvelgo- velagliflozin solution". DailyMed. 8 November 2023. Retrieved 13 December 2023.
  3. ^ "Senvelgo Product information". Union Register of veterinary medicinal products. 22 November 2023. Retrieved 29 August 2024.
  4. ^ a b https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/14320 Public Domain This article incorporates text from this source, which is in the public domain.
  5. ^ a b "Dear Veterinarian Letter regarding important safety conditions associated with the use of Senvelgo (velagliflozin oral solution) for improving glycemic control in certain cats with diabetes mellitus". U.S. Food and Drug Administration. 4 December 2023. Retrieved 13 December 2023. Public Domain This article incorporates text from this source, which is in the public domain.


Allikas: https://en.wikipedia.org/wiki/Velagliflozin
No tags for this post.